Merck Announces Second-Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Merck Announces Second-Quarter 2024 Financial Results
July 30, 2024 6:49 AM EDT
(Updated - July 30, 2024 10:02 AM EDT)
Merck (NYSE: MRK) reported a robust second quarter, with adjusted earnings per share (EPS) of $2.28, surpassing analysts' predictions by $0.12. The pharmaceutical giant also exceeded revenue expectations, posting $16.11 billion against a $15.85 billion consensus.
However, the company's stock has fallen by more than 6% following the report.
The company's chairman and CEO, Robert Davis, attributed the strong quarterly performance to "excellent scientific, commercial and operational execution," highlighting the successful U.S. launch of WINREVAIR and positive European opinions for adults with pulmonary... More
July 30, 2024 6:32 AM EDT
Merck (NYSE: MRK) reported Q2 EPS of $2.28, $0.12 better than the analyst estimate of $2.16. Revenue for the quarter came in at $16.11 billion versus the consensus estimate of $15.85 billion.
GUIDANCE:
Merck sees FY2024 EPS of $7.94-$8.04, versus the consensus of $8.16. Merck sees... More
